Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have…
American Salars Lithium Inc. (‘AMERICAN SALARS’ OR THE ‘COMPANY’) (CSE: USLI, OTC: ASALF, FWB: Z3P, WKN: A3E2NY ) announces…
Saga Metals Corp. (‘SAGA’ or the ‘Company’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company specializing…
(TheNewswire) Brossard, Québec TheNewswire – le 14 mai 2025 – CORPORATION CHARBONE HYDROGÈNE (TSXV: CH OTCQB: CHHYF, FSE: K47…
TSX Venture Exchange: BSK Frankfurt Stock Exchange: MAL2 OTCQB Venture Market (OTC): BKUCF Blue Sky Uranium Corp. (TSXV: BSK) (FSE:…
(TheNewswire) Brossard, Quebec TheNewswire – May 14, 2025 Charbone Hydrogen Corporation (TSXV: CH; OTCQB: CHHYF; FSE: K47) (the ‘Company’…
Electric Royalties Ltd. (TSXV:ELEC)(OTCQB:ELECF) (‘Electric Royalties’ or the ‘Company’) notes that the recent export restrictions imposed by China on…
Endolith has reported a major advance in copper extraction as it pushes the frontiers of microbial science. In collaboration…